12th Co-infection – Presentations

Below are the presentations given during the 12 International Workshop on Co-infection of HIV and Hepatitis Treatment 2016 (provided the speaker has granted us permission to publish their presentation).

  Pre-workshop Education Course - Part I
 
Assessment of fibrosis
Dr. P. Barreiro , Hospital Carlos III, European University , Spain
 
End stage liver disease evaluation
Dr. M. Puoti , ASST Grande Ospedale Metropolitano Niguarda , Italy
 
HCC in HIV- who and how to screen
Dr. R. Bruno , University of Pavia - IRCCS Policlinico S. Matteo , Italy
  Pre-workshop Education Course - Part II
 
Current combinations of DAA for HIV HCV in Europe
Dr. K. Lacombe , Hôpital Saint Antoine , France
 
HDV HBV coinfection
Dr. C. Yurdaydin , University of Ankara Medical School , Turkey
  Session 1: Acute HCV & Oral abstract presentations
 
If , when and how to treat
Dr. C. Boesecke , Universitätsklinikum Bonn , Germany
 
Reinfection diagnosis prevention harm reduction
Dr. P. Ingiliz, Center for Infectiology, Germany
Oral abstract presentation
  Intensive monitoring in MSM with a high risk for Hepatitis C reinfection can impact the incidence of new infections
Dr. S. Popping
  Session 2: Chronic HCV
 
Is prioritization the best way to treat HCV?
Dr. V. Soriano , Hospital Carlos III , Spain
 
Update on HCV treatment for genotype 3
Dr. D. Dieterich , Icahn School of Medicine at Mount Sinai , USA
  Session 3: Difficult to treat HCV cases: Case discussions
 
DAA resistance (Not available) 
Dr. J. Vermehren , Universitätsklinikum , Germany
 
Cirrhosis
Dr. S. Bhagani , Royal Free Hospital , UK
 
DDI challenges and safety with new DAA therapy
Dr. D. Burger , Radboud University Medical Center , The Netherlands
 
ESLD, HCC and options for treatment
Dr. M. Peters , University of California , USA
  Special session: Liver damage, how relevant is it for HCV drugs?
 
Long-term implications of drug toxicity on the liver: What are the mechanisms of liver damage – do they differ for different drug classes or specific agents?
Dr. K. Lacombe , Hôpital Saint Antoine , France
 
The cured liver – what to expect? (Not available)
Dr. M. Peters , University of California , USA
 
Drug-drug interactions between newer HCV DAA and commonly used HIV antiretroviral agents
Dr. D. Burger , Radboud University Medical Center , The Netherlands
  Session 4: Renal disease in HCV & Oral abstract presentations
 
HCV and renal disease in HIV patients
Dr. S. Mauss , Center for HIV and Hepatogastroenterology , Germany
Oral abstract presentations
  Glomerular Filtration Rate Change During HCV Treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected Patients Treated with Tenofovir ± Boosted Protease Inhibitor
Dr. C. Gonçalves
  Are risk factors still relevant for HCV treatment with directly-acting agents against HCV in HIV-HCV-coinfection results from the German hepatitis C cohort (GECCO)?
Dr. S. Mauss
  Daclatasvir + Sofosbuvir +/- Ribavirin in HIV/HCV co-infected patients with advanced liver disease: preliminary data from the Italian Compassionate Use Program
Dr. L. Badia
  Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials in Spain
Dr. V. Soriano
  Future Therapies for HCV and HBV
 
HBV: Future therapies towards a cure
Dr. K. Sherman , University of Cincinnati College of Medicine , USA
 
HCV: New therapies coming in 2016-2017
Dr. M. Sulkowski , Johns Hopkins University , USA